Literature DB >> 9547926

Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy.

R F Deicken1, L Zhou, N Schuff, G Fein, M W Weiner.   

Abstract

BACKGROUND: Previous neuropathological and neuroimaging studies have documented neuronal loss in the hippocampal region in schizophrenia. N-acetylaspartate (NAA) is a neuronal/axonal marker that may be utilized to assess neuronal loss or dysfunction by proton magnetic resonance spectroscopy (1H MRS). This study measured NAA, choline, and creatine in the hippocampal region of patients with schizophrenia using in vivo proton magnetic resonance spectroscopic imaging (1H MRSI).
METHODS: 1H MRSI was performed on the right and left hippocampal regions in 30 chronic schizophrenic patients and 18 control subjects. Concentration estimates of NAA, creatine, and choline were determined.
RESULTS: Relative to the control group, the patients with schizophrenia demonstrated significantly lower NAA in both the right and left hippocampal regions. No group differences in choline were noted; however, there was a trend for creatine to be higher on the left than the right hippocampus in the schizophrenic group. There was also no association between NAA and duration of illness or medication dosage.
CONCLUSIONS: This preliminary study provides support for neuronal dysfunction and/or decreased neuronal density in the hippocampal region. The absence of choline signal elevation does not support accelerated turnover of membrane phospholipids, which might be expected if there were ongoing neuronal atrophy or neuronal necrosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9547926     DOI: 10.1016/S0006-3223(97)00490-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  13 in total

1.  Spatial memory deficits in a virtual reality eight-arm radial maze in schizophrenia.

Authors:  Elena A Spieker; Robert S Astur; Jeffrey T West; Jacqueline A Griego; Laura M Rowland
Journal:  Schizophr Res       Date:  2011-12-09       Impact factor: 4.939

Review 2.  Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis.

Authors:  Nina Vanessa Kraguljac; Meredith Reid; David White; Rebecca Jones; Jan den Hollander; Deborah Lowman; Adrienne Carol Lahti
Journal:  Psychiatry Res       Date:  2012-09-13       Impact factor: 3.222

3.  Evidence for regional hippocampal damage in patients with schizophrenia.

Authors:  Sadhana Singh; Subash Khushu; Pawan Kumar; Satnam Goyal; Triptish Bhatia; Smita N Deshpande
Journal:  Neuroradiology       Date:  2017-12-11       Impact factor: 2.804

4.  Aerobic Exercise in People with Schizophrenia: Neural and Neurocognitive Benefits.

Authors:  Julia Vakhrusheva; Brielle Marino; T Scott Stroup; David Kimhy
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-04

5.  Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia.

Authors:  Ronald R Seese; Joseph O'Neill; Matthew Hudkins; Prabha Siddarth; Jennifer Levitt; Ben Tseng; Keng Nei Wu; Rochelle Caplan
Journal:  Schizophr Res       Date:  2011-08-27       Impact factor: 4.939

6.  Magnetic resonance imaging and spectroscopy in a mouse model of schizophrenia.

Authors:  German Torres; Brian H Hallas; Kenneth W Gross; Joseph A Spernyak; Judith M Horowitz
Journal:  Brain Res Bull       Date:  2007-10-17       Impact factor: 4.077

7.  Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia.

Authors:  Nina V Kraguljac; David M White; Meredith A Reid; Adrienne C Lahti
Journal:  JAMA Psychiatry       Date:  2013-12       Impact factor: 21.596

Review 8.  T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia.

Authors:  Bethany K Bracken; Elizabeth D Rouse; Perry F Renshaw; David P Olson
Journal:  Psychiatry Res       Date:  2013-06-12       Impact factor: 3.222

9.  Neurochemical alterations in methamphetamine-dependent patients treated with cytidine-5'-diphosphate choline: a longitudinal proton magnetic resonance spectroscopy study.

Authors:  Sujung J Yoon; In Kyoon Lyoo; Hengjun J Kim; Tae-Suk Kim; Young Hoon Sung; Namkug Kim; Scott E Lukas; Perry F Renshaw
Journal:  Neuropsychopharmacology       Date:  2009-12-30       Impact factor: 7.853

10.  The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus.

Authors:  Eva Hradetzky; Thomas M Sanderson; Tsz M Tsang; John L Sherwood; Stephen M Fitzjohn; Viktor Lakics; Nadia Malik; Stephanie Schoeffmann; Michael J O'Neill; Tammy Mk Cheng; Laura W Harris; Hassan Rahmoune; Paul C Guest; Emanuele Sher; Graham L Collingridge; Elaine Holmes; Mark D Tricklebank; Sabine Bahn
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.